Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885721 | 0.85 | MEN1 (0.41) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL275563 | 0.82 | ALDH1A1 (0.56) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL13612101 | 0.81 | MEN1 (0.36) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL18227261 | 0.78 | KDM4E (0.56) | TSHRALDH1A1SMN1; SMN2MTNR1AKDM4E | |
| SCHEMBL6289357 | 0.77 | TSHR (0.40) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL7114821 | 0.77 | MEN1 (0.43) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL4879743 | 0.77 | MEN1 (0.39) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL12660498 | 0.77 | MEN1 (0.53) | MEN1KMT2ATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL16853223 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL16853220 | 0.76 | ALDH1A1 (0.55) | MEN1KMT2AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133512-B2 | Drug delivery systems based on catonic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133511-B2 | Drug delivery system based on cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2012-03-13 | — | — | US | disclosed |
| US-7759408-B2 | Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups | BAUSCH & LOMB INCORPORATED (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090274745-A1 | Drug delivery systems based on catonic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090274744-A1 | Drug delivery system based on cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
| US-7579021-B2 | Drug delivery systems based on degradable cationic siloxanyl macromonomers | BAUSCH & LOMB INCORPORATED (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080152540-A1 | PACKAGING SOLUTIONS | BAUSCH & LOMB INCORPORATED (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080075780-A1 | Drug delivery systems based on degradible cationic siloxanyl macromonomers | SANTARUS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070142584-A1 | Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups | LABORATOIRE CHAUVIN S.A.S. (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152540-A1 | PACKAGING SOLUTIONS | AQP1, ARGLU1, CRYZ | MEN1 2673/4885KMT2A 3462/4885HDAC3 2840/4885 |
| US-20070142584-A1 | Silicon-containing monomers end-capped with polymerizable cationic hydrophilic groups | STIM1, ORAI1, ORAI3 | MEN1 440/4885KMT2A 3617/4885HDAC3 1780/4885 |
| US-20090274744-A1 | Drug delivery system based on cationic siloxanyl macromonomers | MSR1, LPXN, SRRM2 | MEN1 659/4885KMT2A 3150/4885HDAC3 1369/4885 |
| US-20090274745-A1 | Drug delivery systems based on catonic siloxanyl macromonomers | MMP13, LPXN, SLC13A2 | MEN1 2150/4885KMT2A 3764/4885HDAC3 1903/4885 |
| US-20080075780-A1 | Drug delivery systems based on degradible cationic siloxanyl macromonomers | MSR1, LPXN, SRRM2 | MEN1 700/4885KMT2A 3351/4885HDAC3 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.